Skip to main content

This site is intended for US healthcare professionals only

SAVINGS AND SUPPORT
TO HELP PATIENTS

START ON THERAPY

IgA=immunoglobulin A.

Otsuka Patient Services logo
Support

Otsuka Patient Services is a free program to help your patients

who have been prescribed VOYXACT® (sibeprenlimab-szsi) start on therapy

Upon opting in, you and your patients will have access to a dedicated team:

  • Field Reimbursement Manager: Access and savings support
  • Care Navigator: Patient device training education

Specialty pharmacy

Once you submit a prescription for VOYXACT, the specialty pharmacy PANTHERx Rare will contact your patient directly and coordinate delivery.

Prescription savings & coverage

The VOYXACT Copay Program*: Eligible patients with commercial insurance may pay as little as $0 for a prescription of VOYXACT.*
*Terms and conditions apply.

VOYXACT Bridge Program: If a patient has challenges with insurance coverage for VOYXACT, the Bridge Program offers temporary access, so your patient isn’t delayed in starting their treatment.
Eligibility required.

*Limitations Apply for the VOYXACT Copay Program. Valid only for those with commercial insurance and if the coverage does not cover the full cost of the VOYXACT prescription. Benefit amount is subject to a (1) monthly maximum based on typical insurance reimbursement rates, including maximum annual out-of-pocket limits established by the Affordable Care Act, and (2) a separate annual maximum benefit of the Affordable Care Act Maximum out-of-pocket amount up to $10,600. Maximum benefits and copay assistance redemption methods may vary as necessary to ensure compliance with these Terms and Conditions. Other restrictions may apply. The VOYXACT Copay Program is not valid under any state or federal healthcare program, including but not limited to Medicare Part D, Medicaid (including Medicaid managed care), Medigap, Veterans Affairs (VA), or Department of Defense or TRICARE programs. No purchase is necessary. Patients must be 18 years and older and a resident of the United States or Puerto Rico and the patient’s prescription is consistent with the FDA-approved labeling. Patients must enroll in the program without the help of any insurer, pharmacy benefit manager, or agent to these entities. Specialty pharmacy assistant enrollment is permitted. The VOYXACT Copay Program is not valid where it is prohibited by law and may not be combined with any third-party rebate, coupon, or offer. Otsuka reserves the right to rescind, revoke, or amend the program and discontinue support at any time without notice.

VOYXACT Bridge Program is not health insurance and is available for eligible, commercially insured patients only. Offer is only available to patients who have been diagnosed with an FDA-approved indication for VOYXACT. No claim for reimbursement for product dispensed pursuant to this offer may be submitted to any third-party payer, additional insurer, or a patient’s state-sponsored commercial insurance. Not available to patients covered by a state or federal healthcare program, including but not limited to Medicare Part D, Medicaid (including Medicaid managed care), Medigap, Veterans Affairs (VA), or Department of Defense (DOD) or TRICARE programs. VOYXACT Bridge Program may be dispensed after primary coverage has been attempted and the patient is experiencing a delay in coverage. Available in a 28-day supply. Refills are subject to limitations. To be eligible for an additional 28-day refill, the patient must be actively pursuing coverage through their insurance. VOYXACT Bridge Program for VOYXACT is limited to 3 28-day dispenses of VOYXACT for patients experiencing a coverage delay. Dispensing of VOYXACT, pursuant to this program, is at the sole discretion of Otsuka. This VOYXACT Bridge Program offer does not require, nor will be made contingent on, purchase requirements of any kind. Otsuka reserves the right to amend, rescind, or discontinue this program at any time without notification. Offer good only in the US and Puerto Rico. Prescription must be provided by a healthcare provider licensed in the US or Puerto Rico. Additional eligibility criteria may apply.

Need something else?

Otsuka Connect Representatives are available to talk with you or your patients. They are available Monday–Friday, 8 AM–8 PM ET at 1-833-869-9228 (1-833-VOYXACT).

Mechanism of Action

See how VOYXACT 
targets APRIL

View the MOA

APRIL=A PRoliferation-Inducing Ligand.

Efficacy

Discover how VOYXACT made an impact

See the Results

Safety

Take a closer look at the 
safety profile

See Safety Info

APRIL=A PRoliferation-Inducing Ligand.

Ready to get started?

A representative can help.

ISI Block Title

INDICATION and IMPORTANT SAFETY INFORMATION for VOYXACT® (sibeprenlimab-szsi)

INDICATION

VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

VOYXACT is contraindicated in patients with serious hypersensitivity to sibeprenlimab-szsi or any of the excipients of VOYXACT.

WARNINGS AND PRECAUTIONS

Immunosuppression and Increased Risk of Infections: VOYXACT suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with chronic or recurring infections may have an increased risk of serious infection. In clinical trials, infections occurred in 49% of patients treated with VOYXACT compared with 45% of patients treated with placebo.

Before initiating VOYXACT, assess patients for active infections. During treatment, monitor patients for signs and symptoms of infection. If a serious infection develops, consider interrupting VOYXACT until the infection is controlled.

Immunosuppression and Immunization Risks: Because of its mechanism of action, VOYXACT may interfere with immune responses to vaccines and increase the risk of infection from live vaccines. Live vaccines are not recommended within 30 days prior to initiation of VOYXACT or during treatment with VOYXACT as safety has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving VOYXACT or on the efficacy of immunizations administered while receiving VOYXACT.

Common Adverse Reactions: The most common adverse reactions (reported in ≥10% of patients treated with VOYXACT and at a higher incidence than placebo) in patients treated with VOYXACT and placebo, respectively, were infections (49% versus 45%) and injection site reactions (24% versus 23%). The most common infection was upper respiratory infection (15% versus 14%), and the most common injection site reaction was injection site erythema (13% versus 12%). Most adverse reactions were reported as mild or moderate in severity and resolved without treatment interruption or discontinuation.

Pregnancy: There are no available data on VOYXACT use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Monoclonal antibodies, such as sibeprenlimab-szsi, can be actively transported across the placenta as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy.

Lactation: There are no data on the presence of sibeprenlimab-szsi in human milk, the effects of sibeprenlimab-szsi on the breastfed infant, or the effects of sibeprenlimab-szsi on milk production.

Pediatric Use: Safety and effectiveness of VOYXACT in pediatric patients have not been established.

Geriatric Use: Clinical studies of VOYXACT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger adult patients.

Pregnant women exposed to VOYXACT, or their healthcare providers, should report VOYXACT exposure by calling 1-833-869-9228 or visiting 
www.VOYXACT.com

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see FULL PRESCRIBING INFORMATION.

Important Safety Information
ISI Block Title

INDICATION and IMPORTANT SAFETY INFORMATION for VOYXACT® (sibeprenlimab-szsi)

INDICATION

VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

VOYXACT is contraindicated in patients with serious hypersensitivity to sibeprenlimab-szsi or any of the excipients of VOYXACT.

WARNINGS AND PRECAUTIONS

Immunosuppression and Increased Risk of Infections: VOYXACT suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with chronic or recurring infections may have an increased risk of serious infection. In clinical trials, infections occurred in 49% of patients treated with VOYXACT compared with 45% of patients treated with placebo.

Before initiating VOYXACT, assess patients for active infections. During treatment, monitor patients for signs and symptoms of infection. If a serious infection develops, consider interrupting VOYXACT until the infection is controlled.

Immunosuppression and Immunization Risks: Because of its mechanism of action, VOYXACT may interfere with immune responses to vaccines and increase the risk of infection from live vaccines. Live vaccines are not recommended within 30 days prior to initiation of VOYXACT or during treatment with VOYXACT as safety has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving VOYXACT or on the efficacy of immunizations administered while receiving VOYXACT.

Common Adverse Reactions: The most common adverse reactions (reported in ≥10% of patients treated with VOYXACT and at a higher incidence than placebo) in patients treated with VOYXACT and placebo, respectively, were infections (49% versus 45%) and injection site reactions (24% versus 23%). The most common infection was upper respiratory infection (15% versus 14%), and the most common injection site reaction was injection site erythema (13% versus 12%). Most adverse reactions were reported as mild or moderate in severity and resolved without treatment interruption or discontinuation.

Pregnancy: There are no available data on VOYXACT use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Monoclonal antibodies, such as sibeprenlimab-szsi, can be actively transported across the placenta as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy.

Lactation: There are no data on the presence of sibeprenlimab-szsi in human milk, the effects of sibeprenlimab-szsi on the breastfed infant, or the effects of sibeprenlimab-szsi on milk production.

Pediatric Use: Safety and effectiveness of VOYXACT in pediatric patients have not been established.

Geriatric Use: Clinical studies of VOYXACT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger adult patients.

Pregnant women exposed to VOYXACT, or their healthcare providers, should report VOYXACT exposure by calling 1-833-869-9228 or visiting 
www.VOYXACT.com

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see FULL PRESCRIBING INFORMATION.